Published in Br J Clin Pharmacol on March 01, 1999
Effect of Arginine Supplementation in the Metabolic Syndrome | NCT02354794
Characterization of the Metabolic Fate of an Oral Arginine Form | NCT02352740
Pharmacokinetics of L-arginine in adults with moderately severe malaria. Antimicrob Agents Chemother (2008) 0.92
Detrimental effects of Bartonella henselae are counteracted by L-arginine and nitric oxide in human endothelial progenitor cells. Proc Natl Acad Sci U S A (2008) 0.90
Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the "L-arginine paradox". Biochem Biophys Res Commun (2011) 0.88
L-arginine supplementation reduces cardiac noradrenergic neurotransmission in spontaneously hypertensive rats. J Mol Cell Cardiol (2009) 0.82
AMP-activated protein kinase regulates L-arginine mediated cellular responses. Nutr Metab (Lond) (2013) 0.79
A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. Clin Pharmacol (2015) 0.77
Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity. Br J Pharmacol (2015) 0.77
Increased plasma availability of L-arginine in the postprandial period decreases the postprandial lipemia in older adults. Nutrition (2012) 0.76
Stimulation of insulin secretion by large-dose oral arginine administration in healthy adults. Exp Ther Med (2013) 0.75
Influence of Circulation System on Estimation of Absorption and Elimination Constant after per oral Drug Administration: A Reanalysis. Indian J Pharm Sci (2013) 0.75
The L-arginine-nitric oxide pathway. N Engl J Med (1993) 14.38
Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet (1992) 2.66
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest (1992) 2.35
Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation (1991) 2.07
Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest (1992) 2.07
Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol (1997) 1.71
Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br J Pharmacol (1992) 1.67
Regulation of enzymes of urea and arginine synthesis. Annu Rev Nutr (1992) 1.49
Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest (1996) 1.48
Arginine needs, physiological state and usual diets. A reevaluation. J Nutr (1986) 1.36
Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol (1996) 1.35
Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation (1994) 1.31
Role of arginine in health and in renal disease. Am J Physiol (1994) 1.26
L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond) (1994) 1.14
The plasma flux and oxidation rate of ornithine adaptively decline with restricted arginine intake. Proc Natl Acad Sci U S A (1994) 1.06
Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis (1995) 1.01
Urea cycle intermediate kinetics and nitrate excretion at normal and "therapeutic" intakes of arginine in humans. Am J Physiol (1995) 1.01
Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol (1997) 0.97
Increases in NO2-/NO3- excretion in the urine as an indicator of the release of endothelium-derived relaxing factor during elevation of blood pressure. Clin Sci (Lond) (1992) 0.94
Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J Am Coll Cardiol (1996) 0.89
L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb (1994) 0.88
Renal tubular transport of amino acids. Clin Chem (1971) 0.84
Arginine pharmacokinetics in humans assessed with an enzymatic assay adapted to a centrifugal analyzer. Clin Chem (1989) 0.83
Basic amino acid transport in renal papilla: microinfusion of Henle's loops and vasa recta. Am J Physiol (1993) 0.83
Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. Hypertension (1997) 0.81
Performance and concentration of amino acids in plasma and urine of young pigs fed diets with excesses of either arginine or lysine. J Anim Sci (1982) 0.80
A simple method for the measurement of arginine in serum. Ann Clin Biochem (1984) 0.80
High-performance liquid chromatographic assay for the quantitation of L-arginine in human plasma. Anal Chem (1996) 0.79
L-arginine improves endothelium-dependent relaxation of conductance and resistance coronary arteries in coronary artery disease. J Cardiovasc Pharmacol (1992) 0.77
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 3.25
G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem (1998) 2.64
Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ Res (1995) 2.55
Fructose-induced insulin resistance and hypertension in rats. Hypertension (1987) 2.43
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 2.35
Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene (1999) 2.27
Implementing clinical practice guidelines while taking account of changing evidence: ATHENA DSS, an easily modifiable decision-support system for managing hypertension in primary care. Proc AMIA Symp (2000) 2.12
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
Experimental characterization and physical modelling of the dose distribution of scanned proton pencil beams. Phys Med Biol (2005) 1.64
Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet (1977) 1.57
Venodilation in Raynaud's disease. Lancet (1993) 1.54
The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol (1998) 1.53
Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev (2000) 1.51
Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest (1992) 1.49
Intensity modulated proton therapy: a clinical example. Med Phys (2001) 1.49
Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr (1979) 1.47
Alpha-adrenergic receptor subtypes: quantitative assessment by ligand binding. Life Sci (1979) 1.42
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS (1998) 1.42
Repeatability of transcranial Doppler measurements of arterial blood flow velocities in healthy subjects. Clin Sci (Lond) (1993) 1.40
Increased urinary transforming growth factor-beta(1) excretion in children with posterior urethral valves. Urology (2000) 1.40
Dynamics of cohesin proteins REC8, STAG3, SMC1 beta and SMC3 are consistent with a role in sister chromatid cohesion during meiosis in human oocytes. Hum Reprod (2010) 1.34
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood (1998) 1.33
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.32
Pharmacokinetics of rifabutin. Antimicrob Agents Chemother (1989) 1.30
Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther (1986) 1.28
Defective bromosulfophthalein clearance in patients with constitutional hepatic dysfunction (Gilbert's syndrome). Gastroenterology (1972) 1.28
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene (2006) 1.27
alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem (1996) 1.26
Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens (1989) 1.24
Alpha-adrenergic receptor subtypes. N Engl J Med (1980) 1.23
Agonist versus antagonist binding to alpha-adrenergic receptors. Proc Natl Acad Sci U S A (1980) 1.22
A role for insulin in the aetiology and course of hypertension? Lancet (1987) 1.21
Vitamin K1 disposition and therapy of warfarin overdose. Lancet (1978) 1.20
Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids (2001) 1.20
Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol (1980) 1.19
A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci U S A (1993) 1.19
Lidocaine blood concentrations during fiberoptic bronchoscopy. Am Rev Respir Dis (1975) 1.14
High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin. J Pharm Sci (1977) 1.14
Inhibition of lipolysis by adenosine is potentiated with age. J Clin Invest (1984) 1.13
Heterogeneity of radioligand binding to alpha-adrenergic receptors. Analysis of guanine nucleotide regulation of agonist binding in relation to receptor subtypes. J Biol Chem (1980) 1.13
A Markov mixed effect regression model for drug compliance. Stat Med (1998) 1.13
Prolonged hyporesponsiveness of vascular smooth muscle contraction after halothane anesthesia in rabbits. Anesth Analg (1985) 1.13
Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr (1994) 1.12
Chronic multifocal osteomyelitis, a new recessive mutation on chromosome 18 of the mouse. Genomics (1991) 1.12
Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet (1995) 1.12
Treatment of paracoccidioidomycosis with itraconazole in a murine model. J Trop Med Hyg (1985) 1.11
High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. J Am Soc Nephrol (1999) 1.11
Offline testing of the ATHENA Hypertension decision support system knowledge base to improve the accuracy of recommendations. AMIA Annu Symp Proc (2006) 1.10
Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen. Pediatr Res (1974) 1.10
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res (2000) 1.09
Differential regulation of the alpha 2-adrenergic receptor by Na+ and guanine nucleotides. Nature (1980) 1.09
Application of salivary concentration data to pharmacokinetic studies with antipyrine. J Pharm Sci (1977) 1.09
Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) (2011) 1.08
Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J (1990) 1.08
Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm (1996) 1.08
Conjugates of catecholamines. II. In vitro and in vivo pharmacological activity of N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. Mol Pharmacol (1983) 1.08
Pharmacological characterizations of adrenergic receptors in human adipocytes. J Clin Invest (1981) 1.06
Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther (1993) 1.05
Engineering human glycoprotein hormone superactive analogues. Nat Biotechnol (1996) 1.04
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther (1998) 1.04
Thermoregulatory reflexes and cutaneous active vasodilation during heat stress in hypertensive humans. J Appl Physiol (1985) (1998) 1.04
Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience (2003) 1.04
Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab (2010) 1.03
Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol (1997) 1.03
Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther (2010) 1.03
Alpha-adrenergic receptors in liver membranes: delineation with subtype selective radioligands. Life Sci (1981) 1.03
Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res (2000) 1.02
Identifying barriers to hypertension guideline adherence using clinician feedback at the point of care. AMIA Annu Symp Proc (2006) 1.02
Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett (2000) 1.02
Age-related decrease in beta adrenergic receptor-mediated vascular smooth muscle relaxation. J Pharmacol Exp Ther (1986) 1.01
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother (1997) 1.01
Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol (2000) 1.01
Cardiomyopathy in a rat model of pheochromocytoma. Morphological and functional alterations. Am J Cardiovasc Pathol (1988) 1.01
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol (2000) 1.00
Desensitization of beta-adrenergic receptors by pheochromocytoma. Endocrinology (1984) 1.00
Heat shock activates c-Src tyrosine kinases and phosphatidylinositol 3-kinase in NIH3T3 fibroblasts. J Biol Chem (1997) 1.00
Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther (2000) 1.00
Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology (1979) 1.00
Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography. J Chromatogr (1982) 0.99
alpha1-Adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther (1999) 0.99
Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Clin Pharmacol Ther (1987) 0.98
Patient safety in guideline-based decision support for hypertension management: ATHENA DSS. Proc AMIA Symp (2001) 0.97
Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther (1988) 0.97
Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet (1980) 0.97
n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J Lipid Res (2007) 0.96
Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol Renal Physiol (2000) 0.96
Tissue engineering: complete autologous valve conduit--a new moulding technique. Thorac Cardiovasc Surg (2001) 0.96
A new approach to quantitation of the various sources of bilrubin in man. J Lab Clin Med (1976) 0.96
Vascular reactivity in obstructive sleep apnea syndrome. Am J Respir Crit Care Med (2000) 0.95
Role of alpha 1 adrenoceptors in the turnover of phosphatidylinositol and of alpha 2 adrenoceptors in the regulation of cyclic AMP accumulation in hamster adipocytes. Life Sci (1980) 0.95
Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes (1988) 0.95